Viewing Study NCT06242834


Ignite Creation Date: 2025-12-25 @ 2:27 AM
Ignite Modification Date: 2025-12-27 @ 8:06 AM
Study NCT ID: NCT06242834
Status: RECRUITING
Last Update Posted: 2025-10-22
First Post: 2024-01-29
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
Sponsor: Northwestern University
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module